The relationship between preoperative T helper cytokines in the ileal mucosa and the pathogenesis of pouchitis

Takahito Kitajima (t-kitajima@clin.med.medic.mie-u.ac.jp)
Mie university Graduate school of medicine

Yoshiki Okita
Mie university Graduate school of medicine

Mikio Kawamura
Mie university Graduate school of medicine

Satoru Kondo
Mie university Graduate school of medicine

Yuji Toiyama
Mie university graduate school of medicine

Keiichi Uchida
Mie university Graduate school of medicine

Masato Kusunoki
Mie university graduate school of medicine

Research article

Keywords: ulcerative colitis, pouchitis, cytokine, IFN-γ, IBD

DOI: https://doi.org/10.21203/rs.2.22289/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Although the etiology of pouchitis remains unknown, inflammatory cytokines are significantly associated with the pathogenesis of pouchitis. The cytokine responses that characterize inflammatory bowel diseases (IBD) are key pathogenic components of the disease. Although cytokine profiles in the colonic mucosa have been investigated in experimental colitis models or IBD patients, cytokine profiles in the ileal mucosa at colectomy have been rarely assessed.

**Aim:** To assess the relationship between pouchitis and T helper (Th) cytokines in the ileal mucosa collected at the time of colectomy and pouch construction.

**Methods:** This retrospective study involved 68 consecutive patients from January 2004 to May 2011 who underwent ileal pouch–anal anastomosis for ulcerative colitis. Samples were obtained from the terminal ileum of resected specimens at time of total colectomy or subtotal colectomy. mRNA expression levels of Th cytokines (IFN-γ, IL-23A, IL-5, IL-13 and IL-17A) were determined.

**Results:** Forty of 68 patients (58.8%) developed pouchitis. There was no association between IL-23A expression levels and incidence of pouchitis ($p=0.301$). Patients with elevated IFN-γ had a significantly higher incidence of pouchitis compared with low IFN-γ patients ($p=0.043$). Univariate analysis demonstrated a total dose of prednisolone >7000 mg administered before colectomy ($p=0.04$) and high IFN-γ expression ($p=0.02$) were significant risk factors for pouchitis onset. In multivariate analysis, elevated IFN-γ messenger(m)RNA levels were significantly associated with pouchitis onset ($p=0.03$).

**Conclusion:** IFN-γ expression in the normal ileal mucosa at the time of colectomy may be an important factor in the pathophysiology of pouchitis.

**Background**

Restorative proctocolectomy and ileal pouch anal anastomosis (IPAA) have been established as standard surgical treatment methods for the management of ulcerative colitis (UC). Pouchitis, a nonspecific inflammatory condition of the ileal pouch, is a well-known complication in patients who undergo IPAA. Pouchitis is defined as nonspecific inflammation developing after intestinal continuity of IPAA. The incidence of pouchitis is 40–70% in UC patients who receive IPAA. Although the immunopathogenesis of pouchitis is unclear, there are two major mechanisms associated with pouchitis: microbial dysbiosis and abnormal immune responses. Whether inflammation of the pouch mucosa represents a recurrence of immune mechanisms in UC or a new form of inflammatory bowel disease (IBD) remains a topic of discussion.

Cytokine responses that characterize IBD are key pathogenic components of the disease. Cytokine responses play key roles in the initiation, evolution, maintenance, and resolution of inflammation. Classically, two types of cytokine responses, determined by T-cell differentiation, have been described: T-helper cell (Th)1 and Th2. Th1, characterized by the production of interferon (IFN)-γ mediates Crohn's
Th2 responses, characterized by the production of interleukin (IL)-5 and IL-13 as well as normal IFN-γ, mediate UC. In addition to these two Th cell types, the recently described Th17 cells, producing IL-17 and IL-23, were reported as a third component of Th cells in various autoimmune disease models. IL-23 is a newly discovered cytokine that has a role in the maintenance and/or expansion of Th17 cells. In the mucosa of IBD, Th17 cells have been proposed to play a key role in intestinal inflammation. Th1 cytokines as well as those secreted from Th17 cells might be associated with CD. Olsen et al. reported that the gene expression levels of IL-17A, IL-23 and IFN-γ correlated with the grade of inflammation in UC, and that IL-17A and IL-23 had a role in mediating inflammation in both forms of IBD. Clarification of these complex networks of Th cytokines might lead to the identification of novel targets for the diagnosis and treatment of CD and UC.

Mucosal concentrations of proinflammatory cytokines including IL-1ß, IL-6 and IL-8 were increased in pouchitis similar to UC. However, cytokine profiles in the ileal mucosa at the time of colectomy have been rarely assessed. Investigating these cytokines in the ileal mucosa might help diagnose the subsequent onset of pouchitis. To the best of our knowledge, no study has examined Th cytokine profiles in ileal mucosa obtained at the time of total colectomy in patients with UC. This study evaluated Th cytokines in the ileal mucosa from UC patients at the time of total colectomy, and tested the predictive value of these cytokines for the onset of pouchitis.

Methods

Patients and specimens

From 2004 to 2011, this study included 183 patients who underwent IPAA in our institution. One hundred fifteen patients excluded for the following reasons: unable to obtain the frozen tissue samples of ileal mucosa because of emergency surgery (subtotal colectomy) (n=65), poor quality of samples (n=12) and lost to follow-up (n=38). In total, frozen tissue samples of ileal mucosa were obtained from 68 patients who underwent IPAA in our institution. Samples were obtained from the terminal ileum of resected specimens at time of total colectomy or subtotal colectomy. Patients with obvious backwash ileitis were excluded. Samples were soaked in RNA later and stored at −80°C until RNA extraction. The protocol for this research project has been approved by a suitably constituted Ethics Committee of the institution and it conforms to the provisions of the Declaration of Helsinki. All informed consent was obtained from the subjects and guardians.

Surgical procedure and diagnosis of pouchitis

All patients underwent IPAA and routinely performed endoscopy each year after stoma closure. In addition, patients with suspected pouchitis were assessed by endoscopic assessments. Patients with pouchitis were diagnosed by a modified Pouchitis Disease Activity Index (mPDAI) score ≥5. Patients with CD of pouch were diagnosed with stenosing, fistulising and with no granulomas during follow-up. Patients with CD of the pouch and Secondary pouchitis (pouch ischemia, anastomotic stricture, pelvic

Page 3/12
sepsis, Cytomegalovirus infection, Clostridium difficile infection, and regular use of nonsteroidal anti-inflammatory drugs) were excluded. The onset of pouchitis was defined as the time from stoma closure to clinical and endoscopic diagnosis at the first episode. Acute antibiotic-responsive pouchitis (ADP) was defined as episodes of symptomatic pouch inflammation occurring fewer than 4 times per year with symptomatic response to a 2-week course of a single antibiotic such as ciprofloxacin. Chronic antibiotic-refractory pouchitis (CARP) included patients with greater than 4 episodes of symptomatic pouch inflammation per year, individuals who require continuous antibiotic therapy to maintain symptom remission, or patients whose symptoms were refractory to antibiotic therapy.\(^{20}\)

**RNA extraction and cDNA synthesis**

Ileal mucosa was homogenized with a Mixer Mill MM 300 homogenizer (Qiagen, Chatsworth, CA, USA). Total RNA was isolated using a RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions. Then, purity and concentration of RNA was estimated with Nano-Drop. Pure RNA was obtained with a A260/A280 ratio of 2.0–2.2. Degraded RNA could be detected with different ratio. cDNA was synthesized from 5.0 mg total RNA with random hexamer primers and Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions.

**Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)**

qRT-PCR analysis was performed using the TaqMan universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA). We investigated the mRNA expression of 5 cytokines in the terminal ileum focusing on Th2 responses (IL-5, IL-6, IL-13, IL-17A and IL-23), and IFN-γ. The relative abundance of target transcripts was measured using TaqMan probes (Applied Biosystems, Foster City, CA, USA) for IFN-γ (Assay ID: Hs00989291_m1), IL-5 (Assay ID: Hs01548712_g1), IL-13 (Assay ID: Hs00174379_m1), IL-17A (Assay ID: Hs001743883_m1), and IL-23A (Assay ID: Hs00900828_g1). Glyceraldehyde-3-phosphate dehydrogenase: GAPDH (Assay ID, Hs02758991_g1; Applied Biosystems) was measured as an internal housekeeping gene. cDNA was amplified and quantified using Applied Biosystems StepOne Plus Real-Time PCR System and analyzed by Software version 2.2.2 (Applied Biosystems).

**Quantification of the relative expression levels of Th cytokines**

Relative gene expression was determined using the standard curve method. Standard curves and line equations were generated using five-fold serially diluted solutions of cDNA generated by the reverse transcription of qPCR Human Reference Total RNA (Clontech, Mountain View, CA, USA). All standard curves were linear in the analyzed range with an acceptable correlation coefficient ($R^2$). Target gene expression was calculated from the standard curve followed by the quantitative normalization of cDNA in each sample using GAPDH as an internal control. Assays were performed in duplicate for each sample and the mean value was used for analysis.

**Statistical analysis**
Results were expressed as median values (interquartile range). The cutoff value of each continuous variable was determined by the median value. Comparisons were performed using non-parametric Wilcoxon signed-rank test for continuous variables. Cumulative incidence of pouchitis was evaluated by the Kaplan-Meier method. Differences between two groups were determined by the log-rank test. Cox proportional hazard regression analysis was used to evaluate the independent influence of factors on the onset of pouchitis. All statistical analyses were carried out using JMP 10 for Windows software (SAS Institute, Cary, NC, USA). Two-sided $p$-values <0.05 were considered statistically significant.

**Results**

**Patient characteristics.**

Sixty-eight patients (male/female; 39/29, median age; 32 years (11–62 years)) were enrolled in this study. The median follow-up period was 40 months (0–117 months). Among these patients, 40 (58.8%) developed pouchitis (Figure 1). Patient characteristics are shown in Table 1.

**Expression levels of Th cytokines.**

The mRNA expression levels of Th cytokines (IFN-$\gamma$, IL-23A, IL-5, IL-13 and IL-17A) were calculated. More than half of the samples were below the level of detection in IL-5, IL-13 and IL-17A assays. These cytokines were excluded from further analysis.

**Cumulative incidence of pouchitis after IPAA according to mRNA levels of Th cytokines**

The cumulative incidence of pouchitis according to the expression levels of IFN-$\gamma$ and IL-23A are shown in Figure 2. Although there was no association between IL-23A expression levels and the incidence of pouchitis ($p$=0.301), patients with elevated IFN-$\gamma$ had a significantly higher incidence of pouchitis than those with low levels of IFN-$\gamma$ ($p$=0.043). Because only IFN-$\gamma$ was associated with the onset of pouchitis, we focused the rest of our study on IFN-$\gamma$.

**Relationship between IFN-$\gamma$ and preoperative clinicopathologic data**

The relationship between pouchitis and preoperative clinicopathologic factors is shown in Table 2. There was a significant difference between IFN-$\gamma$ level and severity of colitis, and patients with elevated C-reactive protein had a trend for higher IFN-$\gamma$ mRNA levels. However, there was no correlation between IFN-$\gamma$ and type of pouchitis. According to univariate analysis, a total dose of prednisolone $>$7000 mg administered before colectomy and IFN-$\gamma$ were identified as significant risk factors for the onset of pouchitis (Table 3). In addition, multivariate analysis showed that elevated IFN-$\gamma$ mRNA levels were significantly associated with the onset of pouchitis.

**Discussion**
The etiology of pouchitis is unknown, but numerous risk factors have been identified. Increased incidence of pouchitis in patients with extraintestinal manifestations\textsuperscript{21-25}, younger age\textsuperscript{25}, shorter disease duration\textsuperscript{2}, extent of disease\textsuperscript{2,25}, more severe preoperative clinical course, steroid dependency\textsuperscript{26} and primary sclerosing cholangitis\textsuperscript{27-29} have been reported. Other studies have reported that even pre- and postoperative use of biologics\textsuperscript{30}, steroid use before colectomy\textsuperscript{24,25}, and postoperative use of nonsteroidal anti-inflammatory drugs\textsuperscript{23}, have significantly correlated with pouchitis. However, in our study, these factors are no statistical difference between the pouchitis and no pouchitis groups. Therefore, additional risk factors or aetiologic factors are needed to help predict which patients are at risk of pouchitis. In our study, only IFN-\(\gamma\) mRNA expressions in patients who developed pouchitis were significantly higher than in patients without pouchitis (\(p=0.043\)). In addition, multivariate analysis demonstrated that elevated IFN-\(\gamma\) mRNA levels was an independent risk factor for the onset of pouchitis.

Pouchitis is a heterogeneous disorder with a combination of various underlying case. Acute pouchitis may be more attributable to dysbiosis in the ileal pouch. ADP, which is predominately microbially mediated, requires antibiotic therapy to maintain symptom remission. On the other hands, CARP may be a result of abnormal host immune response. Thus, a subgroup of patients with CARP does not respond to standard antibiotic therapy\textsuperscript{4,31-33}. The treatment of choice is immunosuppressive therapy with a good response in the treatment of CARP and Crohn's pouchitis\textsuperscript{34-36}. Therefore, when discussing risk factors or predicting factors for pouchitis, it is important to accurately phenotype patients with pouchitis. Our data suggest that IFN-\(\gamma\) expression in ileal mucosa is slightly lower in patients with CARP than those with ADP, although not significant, since Crohn's pouchitis excluded in this study. Further large number study are needs to confirm the accurate correlation between IFN-\(\gamma\) and immune mediated pouchitis.

IFN-\(\gamma\), a cytokine secreted by activated T cells and natural killer (NK) cells, promotes inflammation by activating macrophages and upregulating the expression of cell adhesion molecules\textsuperscript{37}. Furthermore, increased IFN-\(\gamma\) production might be responsible for the tissue damage observed in pouchitis because IFN-\(\gamma\) sustains cytotoxic reactions\textsuperscript{38}. Signal transducer and activator of transcription (STAT)\textsuperscript{1} is part of the signaling pathway of other cytokines/growth factor receptors as well as be a hallmark of IFN-\(\gamma\) receptor signal transduction\textsuperscript{39-41}. Previous studies investigating activation and expression of nuclear factor-kappa B (NF-\(\kappa\)B) and members of the STAT family has positive correlation with the activation of cytokine transcription factors in IBD\textsuperscript{39-41}. Although increased NF-\(\kappa\)B activation was more predominant in CD than in UC, activation and expression of STAT1 were increased in UC compared with CD and normal controls\textsuperscript{41-43}. A study investigating intracellular cytokine data reported that the pathophysiology of small-intestinal inflammation occurring after colectomy in patients with UC might be associated with a Th2 cytokine phenotype\textsuperscript{44}. Additionally, there was a significant increase in the number of IFN-\(\gamma\) producing mononuclear cells in patients with UC with pouchitis compared with UC patients without pouchitis\textsuperscript{45}. Furthermore, there was a tendency towards increased levels of IFN-\(\gamma\) and STAT1 in patients with UC, even without clinical and endoscopic evidence of pouchitis\textsuperscript{46}. Of note, the normal pouch already indicated high levels of STAT1 expression and activation compared with normal preoperative ileum\textsuperscript{42}. 


There are some limitations in this cohort. First, this retrospective study included a limited number of patients with geographical reason from a single cohort. We were unable to detect the genuine number of the patients with pouchitis. Therefore, the finding needs to be validated in a larger prospective cohort. Second, the short follow-up time duration was insufficient to evaluate incidence of pouchitis. Third, we analyzed specific 5 cytokines which might be suggested with incidence of pouchitis in this study. Therefore, further comprehensive analyses of ileal mucosal cytokines related with pouchitis are needed. Nevertheless, our findings suggest that IFN-γ expression in the normal ileal mucosa at the time of colectomy may be an important factor in the pathophysiology of pouchitis. However, further proteomics approach such as ELISA, immunohistochemical analysis or Western blot are needed to confirm the real IFN-γ expression in the ileal mucosa.

**Conclusions**

IFN-γ expression in the normal ileal mucosa at the time of colectomy may be an important factor in the pathophysiology of pouchitis. Further research is required to determine the physiological role of IFN-γ.

**Abbreviations**

Our data suggest that IFN-γ expression in the normal ileal mucosa at the time of colectomy may be an important factor in the pathophysiology of pouchitis. Further research is required to determine the physiological role of IFN-γ.

**Abbreviations**

IBD; inflammatory bowel diseases, Th; T helper, mRNA; messenger RNA, IPAA; ileal pouch anal anastomosis, UC; ulcerative colitis, IFN; interferon, CD; Crohn’s disease, IL; interleukin, ADP; antibiotic dependent pouchitis, CARP; chronic antibiotic refractory pouchitis, NF-κB; nuclear factor-kappa B, STAT; Signal transducer and activator of transcription

**Declarations**

**Ethics approval and consent to participate** The protocol for this research project has been approved by a suitably constituted Ethics Committee of the Institutional Review Board of Mie University Hospital, and it conforms to the provisions of the Declaration of Helsinki. All informed consent was obtained from the subjects and respective guardians with written.

**Consent for publication** Not applicable

**Availability of data and materials:** All data generated or analyzed during this study are included in this published article.

**Competing interests:** The authors declare that they have no competing interests.
Funding: This study has received a research grant from Japanese Society for Palliative Medicine and Mie Medical Research Foundation.

Authors' contributions: Conception: TK, MK, KU; design of the work: TK, MK, YO; the acquisition of data: YO, SK, KU; analysis of data: TK, MK; interpretation of data: TK, MK, YT; drafting of the work: TK, YT, KU, MK. All authors have read and approved the manuscript.

Acknowledgements: We thank Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.

References

1. Coffey JC, Rowan F, Burke J, Dochery NG, Kirwan WO, PR. OC. Pathogenesis of and unifying hypothesis for idiopathic pouchitis. Am J Gastroenterol. 2009;104:1013-1023. 2. Hashava E, Dotan I, Rabau M, Klausner JM, Halpern Z, H. T. Risk factors for chronic pouchitis after ileal pouch-anal anastomosis: a prospective cohort study. Colorectal Dis. 2012;14:1365-1371. 3. Araki T, Kawamura M, Tanaka K, et al. FK506-Binding Protein 5 mRNA Levels in Ileal Mucosa Are Associated with Pouchitis in Patients with Ulcerative Colitis. Dig Dis Sci. Jun 2015;60(6):1617-1623. 4. Hata K, Ishihara S, Nozawa H, et al. Pouchitis after ileal pouch-anal anastomosis in ulcerative colitis: Diagnosis, management, risk factors, and incidence. Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society. Jan 2017;29(1):26-34. 5. T R Mosmann, H Cherwinski, M W Bond, M A Giedlin, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 2005;175(1):5-14. 6. Parronchi P, Romagnani P, Annunziato F, et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol. 1997;150(3):823-832. 7. Breese E, Braegger CP, Corrigan CJ, Walker-Smith JA, TT. M. Interleukin-2- and interferon-y-secreting T cells in normal and diseased human intestinal mucosa. Immunology. 1993;78(1):127-131. 8. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996;157(3):1261-1270. 9. Oppmann B, Lesley R, Blom B, et al. Novel p19 Protein Engages IL-12p40 to Form a Cytokine, IL-23, with Biological Activities Similar as Well as Distinct from IL-12. Immunity. 2000;13(5):715-725. 10. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, AL. G. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 2003;278(3):1910-1914. 11. Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006;116(5):1310-1316. 12. Bettelli E, Oukka M, VK. K. T(H)-17 cells in the circle of immunity and autoimmunity. Nature Immunology. 2007;8(4):345-350. 13. Maloy KJ. The Interleukin-23 / Interleukin-17 axis in intestinal inflammation. Journal of Internal Medicine. 2008;263(6):584-590. 14. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52(1):65-70. 15. Nielsen OH, Kirman I, Rüdiger N, Hendel J, B. V. Upregulation of interleukin-12 and -17 in active inflammatory bowel disease. Scand J Gastroenterol. 2003;38(2):180-185. 16. Olsen T, Rismo R, Cui G, Goll R, Christiansen I, J.
F. TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation. Cytokine. 2011;56(3):633-640. 17. Gionchetti Paolo, Campieri Massimo, Belluzzi Andrea, et al. Macrophage subpopulations and interleukin-1ß tissue levels in pelvic ileal pouch pouches. European J Gastroeneterol Hepatol. 1994;6:217-222. 18. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumor necrosis factor alpha, IL-6 and IL-1ß by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol. 1993;94:174-181. 19. Shen B, Achkar JP, Connor JT, et al. Modified pouchitis disease activity index: a simplified approach to the diagnosis of pouchitis. Dis Colon Rectum. 2003;46(6):748-753. 20. Seril DN, Yao Q, Lasher BA, Shen B. Autoimmune features are associated with chronic antibiotic-refractory pouchitis. Inflammatory bowel diseases. Jan 2015;21(1):110-120. 21. J L Lohmuller, J H Pemberton, R R Dozois, D Ilstrup, Heerden Jv. Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch-anal anastomosis. Ann Surg. 1990;211:622-629. 22. Hata K, Watanabe T, Shinozaki M, H. N. Patients with extraintestinal manifestations have a higher risk of developing pouchitis in ulcerative colitis: multivariate analysis. Scand J Gastroenterol. 2003;38:1055-1058. 23. Achkar JP, Al-Haddad M, Lasher B, et al. Differentiating risk factors for acute and chronic pouchitis. Clin Gastroenterol Hepatol. 2005;3:60-66. 24. Fleshner P, Ippoliti A, Dubinsky M, et al. A prospective multivariate analysis of clinical factors associated with pouchitis after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol. 2007;5:952-958. 25. Lipman JM, Kiran RP, Shen B, Remzi F, VW. F. Perioperative factors during ileal pouch-anal anastomosis predict pouchitis. Dis Colon Rectum. 2011;54:311-317. 26. Kalkan IH, Dağlı Ü, Önder FO, et al. Evaluation of preoperative predictors of development of pouchitis after ileal-pouch-anastomosis in ulcerative colitis. Clin Res Hepatol Gastroenterol. 2012;36:622-627. 27. Penna C, Dozois R, Tremaine W, et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut. 1996;38:234-239. 28. Hoda KM, Collins JF, Knigge KL, KE. D. Predictors of pouchitis after ileal pouch-anal anastomosis: a retrospective review. Dis Colon Rectum. 2008;51:554-560. 29. Wasmuth HH, Tranø G, Endreseth BH, Wibe A, Rydning A, HE. M. Primary sclerosing cholangitis and extraintestinal manifestations in patients with ulcerative colitis and ileal pouch-anal anastomosis. J Gastrointest Surg. 2010;14:1099-1104. 30. Shen B, Yu C, Lian L, et al. Prediction of late-onset pouch failure in patients with restorative proctocolectomy with a nomogram. J Crohns Colitis. 2012;6:198-206. 31. Hurst RD, Chung TP, Rubin M, Michelassi F. The implications of acute pouchitis on the long-term functional results after restorative proctocolectomy. Inflammatory bowel diseases. Nov 1998;4(4):280-284. 32. Mowschenson PM, Critchlow JF, Peppercom MA. Ileal pouch operation: long-term outcome with or without diverting ileostomy. Archives of surgery (Chicago, Ill. : 1960). Apr 2000;135(4):463-465; discussion 465-466. 33. Shen B. Diagnosis and treatment of patients with pouchitis. Drugs. 2003;63(5):453-461. 34. Haveran LA, Sehgal R, Poritz LS, McKenna KJ, Stewart DB, Koltun WA. Infliximab and/or azathioprine in the treatment of Crohn's disease-like complications after IPAA. Diseases of the colon and rectum. Jan 2011;54(1):15-20. 35. Sedano R, Nuñez P, Quera R. DIAGNOSTIC AND MANAGEMENT APPROACH TO POUCHITIS IN INFLAMMATORY BOWEL DISEASE. Arquivos de gastroenterologia. Jan-Mar 2020;57(1):100-106. 36. Shen B. Crohn's disease of the ileal pouch: reality, diagnosis, and management. Inflammatory bowel diseases. Feb 2009;15(2):284-294. 37. Dijkmans R, A. B. Interferon gamma: a master key in the immune system. Curr Opin Immunol. 2009;21:264-271.
1998;1(2):269-274. 38. Fink S, de la Barrera S, Minnucci F, Valdez R, Baliana LM, MC. S. IFN-γ, IL-6 and IL-4 modulate M. leprae- or PPD-specific cytotoxic T cells in leprosy patients. Scand J Immunol. 1993;38:551-558. 39. Nikolaus S, Bauditz J, Gionchetti P, Witt C, Lochs H, S. S. Increased secretion of proinflammatory cytokines by polymorphonuclear neutrophils regulation by Interleukin 10 in inflammatory bowel disease. Gut. 1998;42:470-476. 40. Rogler G, Brand K, Vogl D, et al. Nuclear Factor kappa B is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology. 1998;115:357-369. 41. Schreiber S, Nikolaus S, J. H. Activation of Nuclear Factor kappa B in inflammatory bowel disease. Gut. 1998;42:477-484. 42. Kühbacher T, Gionchetti P, Hampe J, et al. Activation of signal-transducer and activator of transcription 1 (STAT1) in pouchitis. Clin Exp Immunol. 2001;123(3):395-401. 43. Schreiber S, Rosenstiel P, Hampe J, et al. Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut. 2002;51(3):379-385. 44. Akitake R, Nakase H, Tamaoki M, Ueno S, Mikami S, T. C. Modulation of Th1/Th2 balance by infliximab rescues postoperative occurrence of small-intestinal inflammation associated with ulcerative colitis. Dig Dis Sci. 2010;55(6):1781-1784. 45. Stallmach A, Schäfer F, Hoffmann S, et al. Increased state of activation of CD4 positive T cells and elevated interferon gamma production in pouchitis. Gut. 1998;43(4):499-505. 46. Leal RF, Ayrizono ML, Milanski M, et al. Activation of signal transducer and activator of transcription-1 (STAT-1) and differential expression of interferon-gamma and anti-inflammatory proteins in pelvic ileal pouches for ulcerative colitis and familial adenomatous polyposis. Clinical and experimental immunology. Jun 2010;160(3):380-385.

Tables

Due to technical limitations, the tables are only available as a download in the supplemental files section.

Figures
Cumulative risk of developing pouchitis. Cumulative risk of developing pouchitis was 58.8% at the follow-up period (median 40 months (0–117 months)).
Figure 2

The relationship between the cumulative incidence of pouchitis and IL-23A (a) and IFN-γ (b). There was no association between IL-23A expression levels and the incidence of pouchitis (p=0.301) (a). However, the patients with elevated IFN-γ had a significantly higher incidence of pouchitis than those with low levels of IFN-γ (p=0.043).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- pouchitisforDDSTablesfinaleedited.xlsx